Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone805-447-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.36 billion
Profitability
Miscellaneous
Employees23,400
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Wednesday, December 11th. Stockholders of record on Friday, February 14th will be given a dividend of $1.60 per share on Friday, March 6th. This represents a $6.40 annualized dividend and a dividend yield of 2.87%. The ex-dividend date of this dividend is Thursday, February 13th. This is a positive change from Amgen's previous quarterly dividend of $1.45. View Amgen's Dividend History.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings results on Thursday, January, 30th. The medical research company reported $3.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.47 by $0.17. The medical research company had revenue of $6.20 billion for the quarter, compared to the consensus estimate of $6.04 billion. Amgen had a return on equity of 85.52% and a net margin of 33.57%. The company's quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.42 EPS. View Amgen's Earnings History.
When is Amgen's next earnings date?
What guidance has Amgen issued on next quarter's earnings?
Amgen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $14.85-$15.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.10. The company issued revenue guidance of $25.0-$25.6 billion, compared to the consensus revenue estimate of $25.41 billion.
What price target have analysts set for AMGN?
24 brokers have issued 12-month price targets for Amgen's stock. Their forecasts range from $185.00 to $277.00. On average, they anticipate Amgen's share price to reach $238.35 in the next year. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Price Targets for Amgen.
What is the consensus analysts' recommendation for Amgen?
24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
- 2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
- 3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
- 4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)
- 5. Cantor Fitzgerald analysts commented, ". We Reiterate our Neutral rating and $221 Price Target. We are attending the AACR (cancer research meeting) in Atlanta. Amgen presented its preclinical data for 24-minute session. The company’s molecule is targeting the KRAS p.G12C mutation and is a covalent inhibitor. The presentation explained how it identified a unique groove formed by rotation of an adjacent histidine residue (H95). An inactive form of KRAS reveals a small pocket P2 in GDP-KRAS, which is adjacent to cys12. The molecule binds to P2 and H95 and is expected to be dosed orally once daily. 510 has single-digit nanomolar potency and is 1,000x more selective to other KRAS mutants." (4/1/2019)
Has Amgen been receiving favorable news coverage?
Press coverage about AMGN stock has been trending very negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amgen earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Amgen.
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).
What other stocks do shareholders of Amgen own?
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
- Mr. David W. Meline, Exec. VP & CFO (Age 62)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
- Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
- Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)
Who are Amgen's major shareholders?
Amgen's stock is owned by many different of retail and institutional investors. Top institutional investors include Capital Research Global Investors (5.99%), Wealth Quarterback LLC (5.28%), State Street Corp (4.41%), FMR LLC (4.12%), Geode Capital Management LLC (1.70%) and Bank of New York Mellon Corp (1.15%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.
Which major investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including Ruffer LLP, Renaissance Technologies LLC, PGGM Investments, Man Group plc, DekaBank Deutsche Girozentrale, Franklin Resources Inc., Capital International Investors and Victory Capital Management Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar. View Insider Buying and Selling for Amgen.
Which major investors are buying Amgen stock?
AMGN stock was acquired by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Capital Research Global Investors, Johanson Financial Advisors Inc., CI Investments Inc., Annex Advisory Services LLC, Los Angeles Capital Management & Equity Research Inc., MUFG Securities EMEA plc and State Street Corp. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $222.79.
How big of a company is Amgen?
Amgen has a market capitalization of $131.40 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.View Additional Information About Amgen.
What is Amgen's official website?
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (NASDAQ AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
